Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | SLC5A2 | P31639 | 3/20 | 0.31 |
| ▸ | TSHR | P16473 | 2/20 | 0.31 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.31 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.31 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | MAOA | P21397 | 1/20 | 0.30 |
| ▸ | MAOB | P27338 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9094336 | 1.00 | ALDH1A1 (0.32) | ALDH1A1KDM4EPOLBSLC5A2TSHR | |
| SCHEMBL10604754 | 0.88 | MMP9 (0.33) | — | |
| SCHEMBL28863369 | 0.82 | TAAR1 (0.38) | KDM4EPOLBTSHRPDE4DLMNA | |
| SCHEMBL29566431 | 0.82 | TAAR1 (0.38) | KDM4EPOLBTSHRPDE4DLMNA | |
| SCHEMBL9096127 | 0.81 | TSHR (0.38) | ALDH1A1TSHRCYP2C19PDE4DCYP3A4 | |
| SCHEMBL7641953 | 0.81 | TSHR (0.38) | ALDH1A1TSHRCYP2C19PDE4DCYP3A4 | |
| SCHEMBL9094442 | 0.80 | TSHR (0.30) | TSHRCYP2C19 | |
| SCHEMBL7247702 | 0.79 | GRIN2D (0.30) | — | |
| SCHEMBL7247699 | 0.79 | GRIN2D (0.30) | — | |
| SCHEMBL9620579 | 0.77 | TSHR (0.31) | TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2163555-A1 | New pyrazole derivatives and diabetic medicine containing them | Ajinomoto Co., Inc. (JP) | 2010-03-17 | — | — | EP | disclosed |
| US-20100063124-A1 | NEW PYRAZOLE DERIVATIVES AND DIABETIC MEDICINE CONTAINING THEM | AJINOMOTO CO., INC. (JP) | 2010-03-11 | — | — | US | disclosed |
| US-7256209-B2 | Pyrazole derivatives and diabetic medicine containing them | AJINOMOTO CO., INC. (JP) | 2007-08-14 | — | — | US | disclosed |
| US-20070099979-A1 | NEW PYRAZOLE DERIVATIVES AND DIABETIC MEDICINE CONTAINING THEM | AJINOMOTO CO. INC (JP) | 2007-05-03 | — | — | US | disclosed |
| US-6815428-B2 | AS DIABETIC-MEDICINE WHICH IS EASY TO SYNTHESIZE, LESS TOXIC AND HAS HIGHER CURATIVE EFFECT | AJINOMOTO CO., INC. (JP) | 2004-11-09 | — | — | US | disclosed |
| EP-1338603-A1 | NOVEL PYRAZOLE DERIVATIVES AND DIABETES REMEDIES CONTAINING THE SAME | Ajinomoto Co., Inc. (JP) | 2003-08-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070099979-A1 | NEW PYRAZOLE DERIVATIVES AND DIABETIC MEDICINE CONTAINING THEM | DPP4, SLC5A2, SLC5A1 | ALDH1A1 921/4885KDM4E 3289/4885POLB 4602/4885 |
| US-20100063124-A1 | NEW PYRAZOLE DERIVATIVES AND DIABETIC MEDICINE CONTAINING THEM | DPP4, SLC5A2, SLC5A1 | ALDH1A1 921/4885KDM4E 3289/4885POLB 4602/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.